Retatrutide and Body Composition Detailed body composition data from the retatrutide Phase 2 trial has not been fully published
The FDA requires a black box warning about seizure risk (higher with high-fat meals, alcohol, or abrupt alcohol withdrawal) and about neuropsychiatric effects from bupropion including changes in mood, behavior, or suicidal thoughts
Currently, there are four main treatments propelling this market forward: Ozempic and Wegovy (semaglutide: a GLP-1 agonist, developed by Novo Nordisk) Mounjaro and Zepbound (tirzepatide: a dual agonist targeting both GLP-1 and GIP (Gastric inhibitory polypeptide) receptors, developed by Eli Lilly) These medications are administered subcutaneously with the assistance of injection pens
GLP-1 est disponvel no SUS
Incretin-based drugs and renoprotection-is hyperfiltration key
(Physicians will likely stop prescribing a GLP-1 or dual agonist if you receive a pancreatitis diagnosis.) Your doctor should also reevaluate treatment and dosage if you have any other severe side effects
